Anti-Human EGFR (Clone 225) – Biotin
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Expression Host HEK-293 Cells Immunogen Purified EGFR from A431 cells Product Concentration 0.5 mg/ml Formulation This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. State of Matter Liquid Storage and Handling This biotinylated antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? FA, FC, IF, IHC, IP, WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity C225 specifically binds to the human epidermal growth factor receptor (EGFR) on the surface
of cancer cells, inhibiting the receptor's activity and blocking the binding of ligands such as epidermal
growth factor (EGF). Background Epidermal growth factor receptor (EGFR, also known as ErbB1 or HER 1) is a glycoprotein that belongs to
the receptor tyrosine kinase. It plays a role in activating signaling pathways essential, for cellular
proliferation, differentiation, and survival1-3. During embryogenesis organogenesis and throughout
adulthood EGFR is involved in processes such as tissue growth, differentiation, maintenance, and repair2. Moreover, EGFR acts as a host factor for viral entry in diseases like hepatitis B4, hepatitis C5, and
gastroenteritis6. It has also been found to play a role in SARS-CoV-2 infection7-9. Dysregulation of EGFR due to mutation or altered signaling is associated with diseases like Parkinson’s2, Alzheimer’s1, 2, and amyotrophic lateral sclerosis2. Additionally, it has been implicated in the development of cancers including lung, glioblastoma, brain, breast, colorectal, and ovarian3. The binding of ligands to EGFR in cancer cells has been linked to abnormal cell proliferation, invasion, metastasis, angiogenesis, and reduced apoptosis10. Consequently, EGFR serves as a target for cancer treatments including monoclonal humanized antibodies such as panitumumab and cetuximab along with selective small molecule inhibitors11-13. Human Anti-EGFR antibody, clone 225 is a research-grade biosimilar of the monoclonal antibody drug cetuximab. This chimeric antibody contains components from both humans and mice. 225 has been extensively researched in forms of cancer such, as head and neck cell carcinoma, colorectal cancer, and non-small cell lung cancer. Studies have shown that it can be effective when used alongside chemotherapy or radiation therapy presenting an opportunity to enhance outcomes14-22. Antigen Distribution EGFR is overexpressed on the cell surfaces of various tumor cell types and is also
found in the plasma membranes, cytoplasm, and cell junctions of many healthy tissues, including those
associated with the Skin – Epidermis development cluster of The Human Protein Atlas. EGFR is also
found in the blood secretome. Ligand/Receptor Members of the epidermal growth factor (EGF) family NCBI Gene Bank ID UniProt.org Research Area Cancer . Immunology . Neuroscience References & Citations1. Huang XY, Xue LL, Chen TB, et al. Miracle fruit seed as a potential supplement for the treatment of learning and memory disorders in Alzheimer’s disease. Frontiers in Pharmacology. 2023;13. Accessed January 8, 2024. 2. Romano R, Bucci C. Role of EGFR in the Nervous System. Cells. 2020;9(8):1887. 3. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3-20. 4. Iwamoto M, Saso W, Sugiyama R, et al. Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization. Proc Natl Acad Sci U S A. 2019;116(17):8487-8492. 5. Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med. 2011;17(5):589-595. 6. Hu W, Zhang S, Shen Y, Yang Q. Epidermal growth factor receptor is a co-factor for transmissible gastroenteritis virus entry. Virology. 2018;521:33-43. 7. Klann K, Bojkova D, Tascher G, Ciesek S, Münch C, Cinatl J. Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication. Mol Cell. 2020;80(1):164-174.e4. 8. Xu G, Li Y, Zhang S, et al. SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation. Cell Res. 2021;31(12):1230-1243. 9. Wang S, Qiu Z, Hou Y, et al. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Res. 2021;31(2):126-140. 10. Garnock-Jones KP. Necitumumab: First Global Approval. Drugs. 2016;76(2):283-289. 11. Fratto ME, Santini D, Vincenzi B, et al. Targeting EGFR in bilio-pancreatic and liver carcinoma. Front Biosci (Schol Ed). 2011;3(1):16-22. 12. Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G. Pharmacology of epidermal growth factor inhibitors. Int J Biol Markers. 2007;22(4):24-39. 13. Lage A, Crombet T, González G. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. Ann Med. 2003;35(5):327-336. 14. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002;94(5):1593-1611. 15. Nakata E, Hunter N, Mason K, Fan Z, Ang KK, Milas L. C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(4):1163-1173. 16. Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol. 2002;29(5 Suppl 14):55-60. 17. Sur D, Havasi A, Gorzo A, Burz C. A Critical Review of Second-Generation Anti-EGFR Monoclonal Antibodies in Metastatic Colorectal Cancer. Curr Drug Targets. 2021;22(9):1034-1042. 18. Woo J, Palmisiano N, Tester W, Leighton JC. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. Cancer. 2013;119(11):1941-1950. 19. Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ. Mouse-human chimeric anti- epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res. 1998;4(12):2957-2966. 20. Fayette J, Le Chevalier T, Soria JC. [Therapeutic implications of epidermal growth factor receptor in lung cancer]. Bull Cancer. 2003;90 Spec No:S233-240. 21. Hicklin DJ. CCR 20th Anniversary commentary: in search of cetuximab’s first indication-combination therapy with irinotecan in colorectal cancer. Clin Cancer Res. 2015;21(7):1505-1507. 22. Wang C, He X, Zhou B, et al. Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. MAbs. 2011;3(1):67-75. 23. Janmaat ML, Giaccone G. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc). 2003;39 Suppl C:61-80. 24. Stoscheck CM. Enzyme-linked immunosorbent assay for the epidermal growth factor receptor. J Cell Biochem. 1990;43(3):229-241. 25. Ahdi Khosroshahi S, Farajnia S, Ghiamirad M, et al. Development and evaluation of a single domain antibody against human epidermal growth factor receptor (EGFR). Protein Expr Purif. 2016;120:59- 64. 26. Eller JL, Longo SL, Hicklin DJ, Canute GW. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery. 2002;51(4):1005-1013; discussion 1013-1014. Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
---|---|
E360 | |
E361 |
